1. Scrip
  2. >>Business

Ensoma Launches With Takeda Partnership On Myeloablation-Free Gene Therapy

 
• By Alaric DeArment

The company also raised a $70m Series A round and is looking to develop “off-the-shelf” gene therapies adapted to settings with fewer resources.

Takeda Tokyo HQ
Takeda is betting $100m - and potentially more than $1bn - on startup Ensoma. • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. is betting $100m, and potentially more than $1bn, on a start-up company that plans to develop in vivo gene therapies that would remove the need for patients to undergo stem cell collection or myeloablative conditioning, which could enable use of gene therapies in low-resource settings.

Boston-based Ensoma will receive potentially $100m in upfront and preclinical research payments from Takeda, along with up to $1.25bn in development and commercialization milestones, plus royalties. Takeda Ventures also made a $10m equity investment in Ensoma’s $70m Series A funding round, led by 5AM Ventures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.